Olatec gets $40M to put anti-inflammatory in late-stage trial; Enliven goes public, raises $165M
A US and Dutch biotech closed its $40 million Series A to bankroll more studies of its oral anti-inflammatory drug.
Olatec Therapeutics said the financing will fund a late-stage clinical trial of its drug, dapansutrile, an NLRP3 inhibitor. Novartis, Roche and Novo Nordisk have all caught wind of the NLRP3 space, with the latter joining in via a deal with Ventus Therapeutics in NASH and other cardio metabolic diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
